PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENTTHERAPY WITH GENOTROPIN® IN HYPOPITUITARY ADULT PATIENTS

52,554PLN; for patients with age = 9% at 50,139 PLN and for patients with age = 10% at 32,689PLN. In the same patient groups in the analysis for insulin glargine vs pre mix costs per QALY were estimated at 47,171PLN; 40,055PLN; 23,980PLN respectively. CONCLUSIONS: The analysis showed that glargine compared to NPH and premix is a cost effective option for treatment of type 2 diabetes in Poland in patients with baseline HbA1c above 8% and age below 65 years. The results of the cost utility analysis are well below the cost—effectiveness threshold in Poland (equals to 83,239 PLN/QALY).